Wealth Enhancement Advisory Services’s Madrigal Pharmaceuticals MDGL Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.13M	Buy	7,452 +6,837	+1,112%	+$3.61M	﹤0.01%	1374
2026 Q2	$330K	Buy	+615	New	+$315K	﹤0.01%	3103
2026 Q1	–	Sell	-1,513	Closed	-$844K	–	3769
2025 Q4	$844K	Buy	1,513 +805	+114%	+$411K	﹤0.01%	2069
2025 Q3	$309K	Buy	708 +7	+1%	+$2.61K	﹤0.01%	2769
2025 Q2	$210K	Buy	+701	New	+$209K	﹤0.01%	2955
2025 Q1	–	Sell	-680	Closed	-$210K	–	3080
2024 Q4	$210K	Buy	+680	New	+$191K	﹤0.01%	2662
2024 Q2	–	Sell	-973	Closed	-$260K	–	2666
2024 Q1	$260K	Buy	+973	New	+$229K	﹤0.01%	2009

Other funds holding MDGL

EULAV Asset Management Sarasota, Florida $2.77B AUM 18.47% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bourgeon Capital Management Darien, Connecticut $696M AUM 39.92% 1-Year Est. Return

Shikiar Asset Management New York $398M AUM 33.64% 1-Year Est. Return

Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Wealth Enhancement Advisory Services's MDGL Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its Madrigal Pharmaceuticals (MDGL) stake by 1,112% in Q3 2026, buying an estimated $3.61M and bringing the position to 7,452 shares worth $3.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

Wealth Enhancement Advisory Services first reported a position in MDGL in Q1 2024 and has held it in 7 quarters since. 94 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

Wealth Enhancement Advisory Services held 7,452 shares of Madrigal Pharmaceuticals worth $3.13M as of Q3 2026.
Wealth Enhancement Advisory Services bought 6,837 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $3.61M.
Madrigal Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #1374 holding.
Wealth Enhancement Advisory Services first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
94 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.